Boyer, who will serve in the same capacity following the merger with Impax, previously served as CEO and president of North America generics for Teva Pharmaceuticals Inc.
“We are pleased that Andy has joined Amneal and will be leading our commercial organization,” said Chirag Patel, chairman and co-CEO, Amneal. “Andy is an accomplished executive with more than 20 years of pharmaceutical experience architecting commercial strategies designed to capitalize on changing customer needs and market opportunities. His addition further enhances our current leadership team as well as the proposed leadership team for the new Amneal.”
Prior to Teva, Boyer was senior vice president of sales and marketing for the U.S. Generics Division at Allergan PLC.
“I am excited to join Amneal at this important time in the company’s evolution and eventual combination with Impax. Amneal has an exceptional generics portfolio and is well regarded by customers for its quality, value and service. I look forward to working with my new colleagues to build upon that strong foundation and lead the combined organization’s continued advancement as a generic pharmaceuticals leader,” Boyer said.